Published in Cancer Weekly, December 11th, 2001
"Broadening our TAP technology is an important element of our long-term strategy," said Mitchel Sayare, PhD, chairman and CEO of ImmunoGen. "While our product candidates to date have used DM1 as the effector molecule, this new class of taxane-based effector molecules...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.